# To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets

> **NCT00913549** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 36 (actual)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
- **DRUG:** Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)

## Key facts

- **NCT ID:** NCT00913549
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1989-12
- **Primary completion:** 1990-01
- **Final completion:** 1990-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913549, "To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00913549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*